Malika Ammam, PhD,  —

Malika Ammam received her MS degree from the University of Pierre et Marie CURIE in July 2002 and her PhD from the University of Paris Sud XI, France in September 2005. From 2006 to 2007, she worked as a research fellow at the University of Kansas in collaboration with Pinnacle Technology Inc. (USA). From 2007 to 2010, she was a research associate at KU Leuven, Belgium. From 2010 to 2012, she worked at the University of Ontario Institute of Technology in collaboration with Alcohol Countermeasure Systems Corporation, Canada. She held a prestigious Rosalind Franklin fellowship and resigned in 2015. Now, she is a freelancer.

Articles by Malika Ammam

New 3D Structure of Muscle with Fibrosis Could Lead to Therapies for MD, Other Diseases

Researchers recently created a 3D image of the structure and composition of the skeletal muscle, including muscle affected by fibrosis, using multiple imaging techniques coupled with quantitative stereology. The study from a research team at UC San Diego and the Rehabilitation Institute of Chicago, titled “High-resolution three-dimensional reconstruction of fibrotic skeletal muscle…

Road to Better Muscular Dystrophy Treatment Possible with Discovery of New Muscle Repair Pathway

Researchers at the University of Missouri and their colleagues at Carnegie Institution for Science recently identified the pathway of a key gene that regulates muscle fiber production, influences muscle stem cell pool size, and leads to accelerated muscle repair. The study, “Myofiber-specific TEAD1 overexpression drives satellite cell hyperplasia and counters pathological…

Microscopic Views of Calcium Channel May Help Target Therapies for Muscular Dystrophy, Other Muscle Diseases

Researchers at Columbia University Medical Center (CUMC) have succeeded in using high-resolution electron microscopy visualize the intracellular channel involved in the contraction of the skeletal muscle. The study, “Structural Basis for Gating and Activation of RyR1,” was published in Cell. A number of conditions are known to affect various body…

Idera Details Working of 3G Antisense Technology, Potential FSHD Therapy

Idera Pharmaceuticals recently presented pre-clinical data regarding the gene-silencing mechanisms of its third generation antisense (3GA) technology platform, a potential therapeutic for diseases that include, but are not limited to, facioscapulohumeral muscular dystrophy (FSHD). The presentation, “Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides” was made at the…

Molecular Signatures of Key Protein Deficiencies in Muscular Dystrophy Identified in Study

University of Iowa researchers, working in a mouse model of muscular dystrophy (MD), have established new molecular signatures associated with membrane protein complexes that typify the disease, possibly opening the way to new and suitable therapies, according to the study, “Molecular signatures of membrane protein complexes underlying muscular dystrophy,” published in …